SI
FOLD

Sofinnova Investments’s Amicus Therapeutics FOLD Stock Holding History

Sofinnova Investments’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-525,530
Closed -$4.86M – 82
2020
Q1 		$4.86M Buy
525,530
+50,200
+11% +$477K 0.45% 34
2019
Q4 		$4.63M Sell
475,330
-247,644
-34% -$2.27M 0.33% 45
2019
Q3 		$5.8M Buy
722,974
+139,665
+24% +$1.52M 0.52% 41
2019
Q2 		$7.28M Sell
583,309
-799
-0.1% -$10.1K 0.67% 34
2019
Q1 		$7.94M Sell
584,108
-90,528
-13% -$1.11M 0.77% 27
2018
Q4 		$6.46M Buy
674,636
+228,667
+51% +$2.51M 0.81% 27
2018
Q3 		$5.39M Buy
+445,969
New +$6.24M 0.48% 36

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sofinnova Investments's FOLD Position: Q2 2020 in Review

Sofinnova Investments sold out of Amicus Therapeutics (FOLD) in Q2 2020, closing a stake of 525,530 shares — an estimated $4.86M sold.

Sofinnova Investments first reported a position in FOLD in Q3 2018 and held it in 7 quarters. The position peaked at $7.94M in Q1 2019. 226 funds tracked by Wall St. Rank hold FOLD as of Q2 2020.

  • Sofinnova Investments reported no remaining Amicus Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Sofinnova Investments sold 525,530 Amicus Therapeutics shares in Q2 2020, an estimated $4.86M.
  • Sofinnova Investments first reported a position in Amicus Therapeutics in Q3 2018 and held it in 7 quarters.
  • Sofinnova Investments's Amicus Therapeutics position peaked at $7.94M in Q1 2019.
  • 226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2020.

Based on Sofinnova Investments's 13F filing for Q2 2020, filed 13 Aug 2020.